Tagged with BI

Korea After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge new manufacturing facilities to cope with increased demand, a dedication to carrying out technology transfers at half the speed of…

Korea Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of its candidates getting close to phase II clinical trials and the construction of a new manufacturing facility that will enable…

Global David H. Crean, Managing General Partner for Equitos Venture Partners and Cardiff Advisory, highlights news from the recent BIO Convention held face-to-face in San Diego, CA for the first time since the start of the COVID-19 pandemic. After more than two years, the 2022 BIO International Convention (BIO2022) was back…

USA As of July 1st, long-term Merck alumni, Chirfi Guindo, will be returning to the company to lead Human Health Marketing as chief marketing officer for Merck Human Health and will join the Merck Executive Team after almost 5 years at Biogen. Before the parenthesis at Biogen, where he served as…

USA At its recent convention, the first live one in 3 years, the Biotechnology Innovation Organization (BIO) announced the Executive Committee directors for the 2022-2023 term, elected during the event that brought together global thought leaders for 4 days of interactive sessions. This is a critical time for our industry. Our…

Singapore The latest healthcare and pharma news from Singapore, including the partnership between Boehringer Ingelheim and A*STAR for targeted cancer therapies, Amgen’s sponsorship of biotech incubator, NSG BioLabs, and Tessa Therapeutics’ USD 126 million funding round.   Boehringer Ingelheim / A*STAR partner on targeted cancer therapies (BioSpectrum Asia) Boehringer Ingelheim and…

Global How diverse is the biotech workforce? A recent report shows the industry has made progress in terms of diversity, equity, and inclusion (DEI) but still has a way to go. According to the third annual report measuring diversity, equity, and inclusion (DEI) in the biotechnology industry, produced by Coqual in…

Global David H. Crean, Managing General Partner for Equitos Venture Partners and Cardiff Advisory, highlights the latest trends and recommendations for business and corporate development transactions and capital financing of life sciences companies in 2022. We are currently experiencing economic headwinds, making it a challenging time for growth companies such as…

Pharma Legal Handbook An intro to the legal situation for orphan drugs and rare diseases in Colombia. Prepared in association with Cavelier Abogados, a leading global law firm, this is an extract from The Pharma Legal Handbook: Colombia, available to purchase here for GBP 119.   1. What is the definition of Rare Diseases…

Italy Stanislao Caputo, GM at Aristo Pharma Italy, explains the Italian subsidiary’s strategy and how the diversification of its core business led to the acquisition of a portfolio of GSK dermo-cosmetic products. Aristo differentiates itself in the market through its dynamism and its ability to move quickly and diversify its business…

Sweden Anders Blanck, CEO of LIF, the industry organisation for the research-based pharmaceutical industry in Sweden, describes the Sustainability Strategy that the pharma industry in Sweden is now launching. Central to the Strategy is a Manifesto with nine commitments that covers the entire value chain of medicines – from research and…

Taiwan The latest healthcare and pharma news from Taiwan, including the CDMO Bora Pharmaceutical’s acquisition of Eden Biologics assets, the FDA fast track granted to the Taiwanese biomedical group United Biomedical’s Vaxxinity and the Phase II clinical trials completion for a Taiwanese COVID treatment.   Bora consolidates its position in Taiwan’s…